CAZ Investments’s Design Therapeutics DSGN Stock Holding History

CAZ Investments’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$37.2K	Hold	3,500	–	–	0.04%	32
2025 Q4	$32.8K	Sell	3,500 -1,500	-30%	-$11.7K	0.06%	25
2025 Q3	$37.6K	Sell	5,000 -2,500	-33%	-$12.5K	0.07%	21
2025 Q2	$25.3K	Sell	7,500 -7,500	-50%	-$28.1K	0.14%	23
2025 Q1	$58K	Hold	15,000	–	–	0.42%	12
2024 Q4	$93K	Hold	15,000	–	–	0.13%	14
2024 Q3	$81K	Sell	15,000 -25,000	-63%	-$118K	0.05%	21
2024 Q2	$134K	Buy	+40,000	New	+$156K	0.05%	17

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

CAZ Investments's DSGN Position: Q1 2026 in Review

CAZ Investments held its Design Therapeutics (DSGN) position steady in Q1 2026 at 3,500 shares worth $37.2K. The position accounts for 0.04% of the portfolio, ranked #32.

CAZ Investments first reported a position in DSGN in Q2 2024 and has held it in 8 quarters since. The position peaked at $134K in Q2 2024. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

CAZ Investments held 3,500 shares of Design Therapeutics worth $37.2K as of Q1 2026.
CAZ Investments left its Design Therapeutics share count unchanged in Q1 2026.
Design Therapeutics made up 0.04% of CAZ Investments's portfolio in Q1 2026, its #32 holding.
CAZ Investments first reported a position in Design Therapeutics in Q2 2024 and has held it in 8 quarters since.
CAZ Investments's Design Therapeutics position peaked at $134K in Q2 2024.
125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on CAZ Investments's 13F filing for Q1 2026, filed 12 May 2026.